Allen Bott, MD
Neurology with Special Qualifications in Child Neurology · Oakland, CANPI 1770577652
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $289,991 of the $371,554 with a category attached, or 78.0%. 20 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 38.6% of the total. Among neurology with special qualifications in child neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 563 payments — averaging $659.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$144K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60K
- AbbVie$46K
- Axsome Therapeutics, Inc.$39K
- Otsuka America Pharmaceutical, Inc.$24K
- Eisai Inc.$23K
- plus $36K from 14 others
What the payments were for
- Consulting fees$47,61813%
- Speaking & faculty fees$289,99178%
- Travel & lodging$22,6396%
- Food & beverage$11,0323%
- Education$2730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 175 | $143,576 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 78 | $60,110 |
| AbbVie(2 entities) | 109 | $46,417 |
| Axsome Therapeutics, Inc. | 50 | $39,027 |
| Otsuka America Pharmaceutical, Inc. | 42 | $23,559 |
| Eisai Inc. | 27 | $22,661 |
| Teva Pharmaceuticals USA, Inc. | 37 | $19,164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $14,876 |
| Sunovion Pharmaceuticals Inc. | 7 | $1,552 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $274 |
| E.r. Squibb & Sons, L.L.C. | 2 | $63 |
| Biogen | 3 | $61 |
| Lundbeck LLC | 2 | $53 |
| Amneal Pharmaceuticals LLC | 1 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $27 |
| Alkermes, Inc. | 1 | $26 |
| Amgen | 1 | $26 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$371,554 in reported general payments places this provider in the 95th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 51 | $407,494 |
| NuplazidPimavanserin Tartrate | 26 | $119,937 |
| TrintellixVortioxetine Hydrobromide | 121 | $104,463 |
| RexultiBrexpiprazole | 54 | $95,008 |
| EmsamSelegiline | 13 | $53,050 |
| VraylarCariprazine Hcl | 31 | $43,742 |
| AuvelityDextromethorphan Hbr/Bupropion | 44 | $42,947 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 25 | $31,252 |
| UbrelvyUbrogepant | 17 | $25,346 |
| CaplytaLumateperone Tosylate | 14 | $22,619 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $19,994 |
| RytaryCarbidopa/Levodopa | 24 | $15,340 |
| BelsomraSuvorexant | 18 | $10,565 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 203 | $7,570 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $6,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $143,576 | $407,49451 claims |
| Acadia Pharmaceuticals IncNuplazid | $27 | $119,93726 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $14,876 | $104,463121 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $23,559 | $95,00854 claims |
| AbbVieVraylar, Ubrelvy, Namzaric | $46,417 | $75,72860 claims |
| Axsome Therapeutics, Inc.Auvelity | $39,027 | $42,94744 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $60,110 | $22,61914 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $25 | $19,99412 claims |
| Amneal Pharmaceuticals LLCRytary | $30 | $15,34024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 neurology with special qualifications in child neurology providers in California.
Other neurology with special qualifications in child neurology in Oakland
- Jennifer Martelle TuOakland$8K
- Ali MostajeleanOakland$7K
- Michael ChezSacramento$374K
- Joseph SullivanSan Francisco$240K
- Ann SegerenStanford$172K
- Rajsekar RajaramanLos Angeles$134K
- Deborah HolderLos Angeles$130K
- Akash VirupakshaiahSan Francisco$94K
- Brittany PassiakSan Diego$90K
- Kevin ShapiroMadera$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.